Biotime receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Lineage Cell Therapeutics Inc (LCTX)
Lineage Cell Therapeutics Inc stock price live, this page displays NYSE LCTX stock exchange data. View the LCTX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Lineage Cell Therapeutics Inc real time stock price chart below.
What Is the Lineage Cell Therapeutics Inc Stock Price Today?
The Lineage Cell Therapeutics Inc stock price today is 327.1.
What Is the Stock Symbol for Lineage Cell Therapeutics Inc?
The stock symbol for Lineage Cell Therapeutics Inc is ""LCTX.""
What Stock Exchange Does Lineage Cell Therapeutics Inc Trade On?
Lineage Cell Therapeutics Inc is listed and trades on the NYSE stock exchange.
Is Lineage Cell Therapeutics Inc a Good Stock to Buy?
Determining whether Lineage Cell Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LCTX quote. (ISIN: US53566P1093)
What Is the Lineage Cell Therapeutics Inc Stock Price Today?
The Lineage Cell Therapeutics Inc stock price today is 327.1.
What Is the Stock Symbol for Lineage Cell Therapeutics Inc?
The stock symbol for Lineage Cell Therapeutics Inc is ""LCTX.""
What Stock Exchange Does Lineage Cell Therapeutics Inc Trade On?
Lineage Cell Therapeutics Inc is listed and trades on the NYSE stock exchange.
Is Lineage Cell Therapeutics Inc a Good Stock to Buy?
Determining whether Lineage Cell Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LCTX quote. (ISIN: US53566P1093)
327.1
-24.2(-6.89%)
Closed·
Fair Value
An estimate of a Lineage Cell Therapeutics Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
321.0
351.3
52 wk Range
136.9
405.0
LCTX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
LCTX is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a Lineage Cell Therapeutics Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
321.0351.3
52 wk Range
136.9405.0
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
LCTX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Lineage Cell Therapeutics Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings downwards for the upcoming period
- Form 8K Lineage Cell Therapeutics Inc For: 2 July
- Investing.com
- Biotime receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 8K Lineage Cell Therapeutics Inc For: 2 July
- Investing.com
- Form 8K Lineage Cell Therapeutics Inc For: 23 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Lineage Cell Therapeutics Inc Company Profile
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a cell transplant program for an undisclosed indication through a gene editing collaboration, engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Compare LCTX to Peers and Sector
Metrics to compare | LCTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLCTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −13.4x | −5.1x | −0.5x | |
PEG Ratio | −0.32 | −0.08 | 0.00 | |
Price/Book | 2.7x | 4.2x | 2.6x | |
Price / LTM Sales | 22.7x | 10.9x | 3.3x | |
Upside (Analyst Target) | - | 286.9% | 43.5% | |
Fair Value Upside | Unlock | −2.1% | 6.3% | Unlock |
Earnings
Latest Release
May 13, 2025
EPS / Forecast
-0.02 / --
Revenue / Forecast
1.50M / --
People Also Watch
FAQ
What Stock Exchange Does Lineage Cell Therapeutics Inc Trade On?
Lineage Cell Therapeutics Inc is listed and trades on the Tel Aviv Stock Exchange stock exchange.
What Is the Stock Symbol for Lineage Cell Therapeutics Inc?
The stock symbol for Lineage Cell Therapeutics Inc is "LCTX."
What Is the Lineage Cell Therapeutics Inc Market Cap?
As of today, Lineage Cell Therapeutics Inc market cap is 754.70M.
What Is Lineage Cell Therapeutics Inc's Earnings Per Share (TTM)?
The Lineage Cell Therapeutics Inc EPS (TTM) is -0.08.
From a Technical Analysis Perspective, Is LCTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Lineage Cell Therapeutics Inc Stock Split?
Lineage Cell Therapeutics Inc has split 0 times.
How Many Employees Does Lineage Cell Therapeutics Inc Have?
Lineage Cell Therapeutics Inc has 74 employees.
What is the current trading status of Lineage Cell Therapeutics Inc (LCTX)?
As of 05 Aug 2025, Lineage Cell Therapeutics Inc (LCTX) is trading at a price of 327.10, with a previous close of 351.30. The stock has fluctuated within a day range of 321.00 to 351.30, while its 52-week range spans from 136.90 to 405.00.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.